266 related articles for article (PubMed ID: 19338138)
1. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
[TBL] [Abstract][Full Text] [Related]
2. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
Nakayama K; Natori Y; Sato T; Kimura T; Sugiura A; Sato H; Saito T; Ito S; Natori Y
J Lab Clin Med; 2004 Feb; 143(2):106-14. PubMed ID: 14966466
[TBL] [Abstract][Full Text] [Related]
4. Key molecular events in puromycin aminonucleoside nephrosis rats.
Guan N; Ding J; Deng J; Zhang J; Yang J
Pathol Int; 2004 Sep; 54(9):703-11. PubMed ID: 15363039
[TBL] [Abstract][Full Text] [Related]
5. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
Zheng Y; Shirato I; Maeda A; Kobayashi N; Liao J; Shou I; Fukui M; Tomino Y
J Nephrol; 2002; 15(1):36-41. PubMed ID: 11936424
[TBL] [Abstract][Full Text] [Related]
6. Effect of a low-protein diet on expression of non-muscle type myosin heavy-chain isoforms in glomeruli of rats with puromycin aminonucleoside nephrosis.
Koide H; Nakamura T; Kimura K; Ebihara I; Nagai R; Tomino Y
Nephrol Dial Transplant; 1996 Sep; 11(9):1769-74. PubMed ID: 8918620
[TBL] [Abstract][Full Text] [Related]
7. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
[TBL] [Abstract][Full Text] [Related]
8. Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
Radin MJ; Wilke WL; Fettman MJ
Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):279-82. PubMed ID: 3538253
[TBL] [Abstract][Full Text] [Related]
9. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
Ebihara I; Nakamura T; Tomino Y; Koide H
Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
Okada T; Sakaguchi T; Hatamura I; Saji F; Negi S; Otani H; Muragaki Y; Kawachi H; Shigematsu T
Clin Exp Nephrol; 2009 Oct; 13(5):438-446. PubMed ID: 19452240
[TBL] [Abstract][Full Text] [Related]
11. [Bone mesenchymal stem cell transplantation repairs glomerular podocytes in rats with puromycin aminonucleoside-induced nephrosis].
Yang HD; Dong C; Guan FJ; Gao LL; Zhao T; Feng BF
Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):483-7. PubMed ID: 20540862
[TBL] [Abstract][Full Text] [Related]
12. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
Tsuchihashi T; Ueno M; Tominaga M; Kajioka T; Onaka U; Eto K; Goto K
Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
[TBL] [Abstract][Full Text] [Related]
13. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.
Konda T; Enomoto A; Takahara A; Yamamoto H
Biol Pharm Bull; 2006 May; 29(5):933-7. PubMed ID: 16651722
[TBL] [Abstract][Full Text] [Related]
14. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
[TBL] [Abstract][Full Text] [Related]
15. Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.
Kim BS; Park HC; Kang SW; Choi KH; Ha SK; Han DS; Lee HY
Yonsei Med J; 2005 Feb; 46(1):141-8. PubMed ID: 15744817
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural study on nephrin expression in experimental puromycin aminonucleoside nephrosis.
Lee YK; Kwon T; Kim DJ; Huh W; Kim YG; Oh HY; Kawachi H
Nephrol Dial Transplant; 2004 Dec; 19(12):2981-6. PubMed ID: 15385636
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode.
Kawakami H; Kamiie J; Yasuno K; Kobayashi R; Aihara N; Shirota K
Nephrol Dial Transplant; 2012 Apr; 27(4):1324-30. PubMed ID: 21862459
[TBL] [Abstract][Full Text] [Related]
18. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
Seino H; Miyaguchi S; Yamazaki T; Ota S; Yabe R; Suzuki S
Arzneimittelforschung; 2007; 57(8):526-31. PubMed ID: 17915639
[TBL] [Abstract][Full Text] [Related]
19. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.
Yatsu T; Aoki M; Tanaka A
Eur J Pharmacol; 2005 Mar; 510(1-2):121-6. PubMed ID: 15740732
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
